Search

Your search keyword '"Juntas-Morales, Raul"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Juntas-Morales, Raul" Remove constraint Author: "Juntas-Morales, Raul"
89 results on '"Juntas-Morales, Raul"'

Search Results

51. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial

54. Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort

55. A new congenital multicore titinopathy associated with fast myosin heavy chain deficiency

56. ASC‐1 Is a Cell Cycle Regulator Associated with Severe and Mild Forms of Myopathy

57. Implanted Phrenic Stimulation Impairs Local Diaphragm Myofiber Reinnervation in Amyotrophic Lateral Sclerosis

58. Dramatic Weight Loss with Levetiracetam

59. Charcot-Marie-Tooth disease type 2CC due to NEFHvariants causes a progressive, non-length-dependent, motor-predominant phenotype

60. Expanding the Spectrum of AP5Z1‐Related Hereditary Spastic Paraplegia (HSP‐SPG48): A Multicenter Study on a Rare Disease.

62. Les répétitions intermédiaires GGGGCC du gène C9ORF72 ne sont pas un facteur de risque de SLA

63. ASC-1 Is a Cell Cycle Regulator Associated with Severe and Mild Forms of Myopathy.

64. MoBiDiC Prioritization Algorithm, a Free, Accessible, and Efficient Pipeline for Single-Nucleotide Variant Annotation and Prioritization for Next-Generation Sequencing Routine Molecular Diagnosis

65. A Reliable Targeted Next-Generation Sequencing Strategy for Diagnosis of Myopathies and Muscular Dystrophies, Especially for the Giant Titin and Nebulin Genes

66. Clinical phenotype and loss of the slow skeletal muscle troponin T in three new patients with recessive TNNT1 nemaline myopathy

67. Next generation sequencing of a large panel of genes is efficient for diagnosis of children with myopathies and muscular dystrophies, especially for early and / or atypical cases

68. IMMUNO-MODULATION IN AMYOTROPHIC LATERAL SCLEROSIS - A PHASE II STUDY OF SAFETY AND ACTIVITY OF LOW DOSE INTERLEUKIN-2 (IMODALS study) (S3.006)

69. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

70. Liver X Receptor Genes Variants Modulate ALS Phenotype

71. Axonal Neuropathies due to Mutations in Small Heat Shock Proteins: Clinical, Genetic, and Functional Insights into Novel Mutations

73. Bent spine syndrome as the initial symptom of late-onset Pompe disease

76. LRSAM1variants and founder effect in French families with ataxic form of Charcot-Marie-Tooth type 2

79. Etude de la réactivité émotionnelle chez des patients atteints de sclérose latérale amyotrophique

80. Bent spine syndrome as the initial symptom of late-onset Pompe disease.

81. The Use of Peripherally Inserted Central Catheter in Amyotrophic Lateral Sclerosis Patients at a Later Stage.

84. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction

85. Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation.

86. FHL1 is a key player of chikungunya virus tropism and pathogenesis.

87. Charcot-Marie-Tooth disease type 2CC due to NEFH variants causes a progressive, non-length-dependent, motor-predominant phenotype.

88. Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme.

89. [Environmental factors in ALS].

Catalog

Books, media, physical & digital resources